+Combined preparations and pharmaceutical compositions comprising: (a) LAG 3 protein or a derivative thereof that is able to bind to MHC class II molecules and (b) a programmed cell death protein 1 (PD 1) pathway inhibitor are described. The PD 1 pathway inhibitor such as an anti PD 1 antibody or an anti PD L1 antibody and a soluble derivative of LAG 3 acting as an APC activator together synergistically activate T cells (in particular CD8 T cells). Use of the combined preparations and compositions as medicaments in particular for the treatment of cancer or infection and to methods for the treatment of cancer or infection is described.
